SCYNEXIS, Inc

(NASDAQ:SCYX)

Latest On SCYNEXIS, Inc (SCYX):

Date/Time Type Description Signal Details
2023-05-20 04:36 ESTNewsScynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral RatingN/A
2023-05-11 10:11 ESTNewsSCYNEXIS GAAP EPS of -$0.71, revenue of $1.13MN/A
2023-04-01 01:36 ESTNewsScynexis: Licensing Deal With GSK, Upgrading To A Hold Rating From A SellN/A
2023-03-31 10:02 ESTNewsSCYNEXIS GAAP EPS of -$0.30 beats by $0.10, revenue of $1.4M beats by $0.13MN/A
2023-03-30 12:23 ESTNewsSCYNEXIS jumps 92% on licensing deal with GSK for anti-fungal agentN/A
2023-03-24 00:13 ESTNewsCidara off 27% despite FDA nod amid selloff in antifungal spaceN/A
2023-03-22 16:57 ESTNewsDeadly fungal infection sweeps across U.S.N/A
2023-03-01 16:04 ESTNewsScynexis adds 23% most in over two years as Guggenheim says BuyN/A
2023-01-09 07:40 ESTNewsScynexis: New rVVC Label And Black-Boxed Warning, Maintaining A Sell RatingN/A
2022-12-01 17:12 ESTNewsSCYNEXIS wins FDA label expansion for anti-fungal therapyN/A
2022-11-30 23:23 ESTNewsResearchers get $3M NIH grant to study Scynexis' antifungal drug SCY-247N/A
2022-11-10 05:26 ESTNewsSCYNEXIS, Inc. (SCYX) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 11:50 ESTNewsSCYNEXIS GAAP EPS of -$0.62 misses by $0.12, revenue of $1.56M misses by $0.5MN/A
2022-10-30 14:49 ESTNewsScynexis: No Compelling Reason To InvestN/A
2022-10-25 16:11 ESTNewsScynexis appoints Ivor Macleod as CFON/A
2022-10-20 21:40 ESTNewsScynexis announces changes to leadership and strategic directionN/A
2022-08-27 02:31 ESTNewsScynexis: Uninvestible At This Point, Downgrading To A Sell RatingN/A
2022-08-15 21:14 ESTNewsSCYNEXIS GAAP EPS of -$0.31 beats by $0.28, revenue of $1.32M misses by $0.32MN/A
2022-08-15 21:14 ESTNewsScynexis stock rises as Brexafemme sales nearly double Q/QN/A
2022-08-15 21:14 ESTNewsSCYNEXIS, Inc. (SCYX) CEO Dr. Marco Taglietti on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-13 00:47 ESTNewsSCYNEXIS Q2 2022 Earnings PreviewN/A
2022-08-01 15:32 ESTNewsFDA accepts Scynexis' application to expand label for vaginal yeast infections treatmentN/A
2022-07-19 22:11 ESTNewsSCYNEXIS gains after favorable data for antifungal agent in new indicationN/A
2022-05-13 00:28 ESTNewsSCYNEXIS GAAP EPS of -$0.17, revenue of $0.7MN/A
2022-05-13 00:27 ESTNewsSCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-12 04:27 ESTNewsSCYNEXIS Q1 2022 Earnings PreviewN/A
2022-04-22 17:32 ESTNewsScynexis stock falls 17% despite fungal infection drug showing promise in interim data from 2 late-stage studiesN/A
2022-04-22 17:32 ESTNewsSCYNEXIS plunges on pricing $45M in stock and pre-funded warrants offeringN/A
2022-04-22 00:40 ESTNewsScynexis initiates stock offering planN/A
2022-03-30 06:52 ESTNewsScynexis stock fall 16% amid Q4 resultsN/A
2022-03-30 06:52 ESTNewsSCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-29 10:24 ESTNewsSCYNEXIS GAAP EPS of -$1.05 misses by $0.28, revenue of $0.6M misses by $0.56MN/A
2022-03-08 01:35 ESTNewsScynexis, Inc.: Speculative Buy, Michael Burry Sold, But I Am BuyingN/A
2022-02-10 15:02 ESTNewsSCYNEXIS says Phase 3 trial for ibrexafungerp met main goal in vaginal yeast infectionN/A
2022-02-03 17:09 ESTNewsSCYNEXIS grants stock options and RSUs to five new employeesN/A
2021-12-15 17:44 ESTNewsScynexis' ibrexafungerp an Orphan Drug in Europe for invasive candidiasisN/A
2021-12-06 21:52 ESTNewsScynexis launches late-stage oral ibrexafungerp study in invasive candidiasisN/A
2021-12-03 20:16 ESTNewsSCYNEXIS reports inducement grants under Nasdaq listing ruleN/A
2021-11-10 15:22 ESTNewsSCYNEXIS EPS beats by $0.67, beats on revenueN/A
2021-11-10 15:22 ESTNewsSCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-09 16:26 ESTNewsSCYNEXIS Q3 2021 Earnings PreviewN/A
2021-10-29 23:58 ESTNewsSCYNEXIS CFO Eric Francois to resignN/A
2021-10-21 16:28 ESTNewsScynexis rises on publishing of phase 3 data of vaginal yeast therapy BREXAFEMMEN/A
2021-10-11 17:09 ESTNewsSCYNEX highlights preclinical data from ibrexafungerp mucormycosis studyN/A
2021-09-29 22:55 ESTNewsScynexis reports interim data from late-stage ibrexafungerp study in fungal infectionsN/A
2021-09-23 11:27 ESTNewsSCYNEXIS launches Brexafemme vaginal yeast infection treatment in the U.S.N/A
2021-08-17 00:21 ESTNewsSCYNEXIS EPS beats by $0.40N/A
2021-07-30 01:04 ESTNewsPooled data demonstrates efficacy of SCYNEXIS' Brexafemme for vaginal yeast infectionsN/A
2021-07-27 15:56 ESTNewsScynexis: Leading The Yeast Infection Treatment IndustryN/A
2021-07-21 23:46 ESTNewsFDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatmentN/A

About SCYNEXIS, Inc (SCYX):

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

SCYX Quotes by TradingView

See Advanced Chart

General

  • Name SCYNEXIS, Inc
  • Symbol SCYX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 27
  • Last Split Factor1:10
  • Last Split Date2020-07-17
  • Fiscal Year EndDecember
  • IPO Date2014-05-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.scynexis.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1049.19
  • Price/Book (Most Recent Quarter) 17.39
  • Enterprise Value Revenue 1169.28
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.93
  • Return on Assets -88%
  • Return on Equity -343%
  • Earnings Per Share -$0.59
  • Revenue Per Share $0
  • Gross Profit 121000
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 160.99 million
  • EBITDA -38041000
  • PE Ratio -1.56
  • Analyst Target Price $30.57
  • Book Value Per Share $0.89
View More

Share Statistics

  • Shares Outstanding 19.28 million
  • Shares Float 7.87 million
  • % Held by Insiders 372%
  • % Held by Institutions 39.22%
  • Shares Short 1.11 million
  • Shares Short Prior Month 789311
  • Short Ratio 1.54
  • Short % of Float 6%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 2.1
  • 52 Week High $10.4
  • 52 Week Low $4.2
  • 50 Day Moving Average 8.51
  • 200 Day Moving Average 6.6
View More

Dividends

  • Dividend Date 2020-07-17
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

SCYNEXIS, Inc (SCYX) Dividend Calendar:

SCYX's last dividend payment was made to shareholders on July 17, 2020.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

SCYNEXIS, Inc (SCYX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-06$N/A$0.09-$1.09108.26%
2020-06-302020-08-10$N/A-$0.64-$1.1946.22%
2020-03-312020-05-11$N/A-$0.70-$1.5053.33%
2019-12-312020-03-11$N/A-$2.20-$1.70-29.41%
2019-09-302019-11-12$N/A-$1.40-$2.2337.31%
2019-06-302019-08-07$57000-$1.60-$1.9216.52%
2019-03-312019-05-08$64000-$4.60-$1.97-133.89%
2018-12-312019-03-14$64000$0.60-$1.48140.45%
2018-09-302018-11-13$64000$0.10-$1.78105.61%
2018-06-302018-08-09$64000-$2.30-$1.68-37.31%
2018-03-312018-05-08$64000-$1.20-$1.9438.14%
2017-12-312018-03-13$64000-$2.70-$2.855.26%
2017-09-302017-11-07$64000-$3.10-$3.254.62%
2017-06-302017-08-08$65000-$1.60-$2.5737.66%
2017-03-312017-05-08$64000-$1.90-$3.2541.54%
2016-12-312017-03-13$64000-$1.40-$3.5860.93%
2016-09-302016-11-07$64000-$4.80-$4.983.52%
2016-06-302016-08-08$65000-$5.60-$5.20-7.69%
2016-03-312016-05-09$64000-$5.20-$6.2016.13%
2015-12-312016-03-07$-3168000-$5.50-$5.774.62%
2015-09-302015-11-13$64000-$0.60-$0.623.23%
2015-06-302015-08-19$64000-$0.78-$0.45-73.33%
2015-03-312015-05-15$3.3 million-$0.75-$0.43-74.42%
2014-12-312015-03-30$5.3 million-$0.45-$0.7136.62%
2014-09-302014-11-13$4.38 million-$0.45-$0.5213.46%
2014-06-302014-08-13$4.64 million-$0.73-$0.40-82.5%
2014-03-312014-06-16$4.71 million-$65.74

SCYNEXIS, Inc (SCYX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

SCYNEXIS, Inc (SCYX) Chart:

SCYNEXIS, Inc (SCYX) News:

Below you will find a list of latest news for SCYNEXIS, Inc (SCYX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

SCYNEXIS, Inc (SCYX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-12-202.50.05CALL5 31299.1FALSE0.050
2024-12-2050.05CALL0 2390FALSE00
2024-12-207.50.05CALL0 430FALSE00
2024-12-202.50.9PUT0 78135.83TRUE00
2024-12-2050PUT0 0312.81TRUE00
2024-12-207.55.6PUT0 0216.76TRUE00
2025-03-212.50.2CALL0 19599.18FALSE00
2025-03-2150.1CALL0 2020FALSE00
2025-03-217.50CALL0 00FALSE00
2025-03-212.51PUT0 1197.44TRUE00
2025-03-2150PUT0 0221.92TRUE00
2025-03-217.50PUT0 0256.64TRUE00

Latest SCYX Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST150$1.785
Jun 13, 2022 7:58 PM EST100$1.785
Jun 13, 2022 7:58 PM EST75$1.785
Jun 13, 2022 7:59 PM EST100$1.78
Jun 13, 2022 7:59 PM EST7$1.77

SCYNEXIS, Inc (SCYX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1178253/000114036120012728/0001140361-20-012728-index.htm
2018-09-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1178253/000000000018028195/0000000000-18-028195-index.htm
2019-03-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1178253/000000000019006038/0000000000-19-006038-index.htm
2020-05-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1178253/000000000020004005/0000000000-20-004005-index.htm
2020-09-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1178253/000000000020008750/0000000000-20-008750-index.htm
2018-03-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000091957418002464/0000919574-18-002464-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000091957419001805/0000919574-19-001805-index.htm
2019-12-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000091957419007758/0000919574-19-007758-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000091957420001628/0000919574-20-001628-index.htm
2018-10-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000093583618000585/0000935836-18-000585-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000093583619000106/0000935836-19-000106-index.htm
2018-08-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1178253/000095012318009278/0000950123-18-009278-index.htm
2019-12-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000110465919075584/0001104659-19-075584-index.htm
2020-05-15PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1178253/000114036120011765/0001140361-20-011765-index.htm
2020-05-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1178253/000114036120012728/0001140361-20-012728-index.htm
2018-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1178253/000119312518143497/0001193125-18-143497-index.htm
2018-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1178253/000119312518143529/0001193125-18-143529-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000119312519035454/0001193125-19-035454-index.htm
2019-12-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1178253/000119312519309323/0001193125-19-309323-index.htm
2019-12-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1178253/000119312519311468/0001193125-19-311468-index.htm
2019-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000119312519312768/0001193125-19-312768-index.htm
2020-04-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000119312520113337/0001193125-20-113337-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000119312520188901/0001193125-20-188901-index.htm
2018-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118018707/0001209191-18-018707-index.htm
2018-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118018708/0001209191-18-018708-index.htm
2018-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118018709/0001209191-18-018709-index.htm
2018-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118018711/0001209191-18-018711-index.htm
2018-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118018877/0001209191-18-018877-index.htm
2018-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118022265/0001209191-18-022265-index.htm
2018-04-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118023923/0001209191-18-023923-index.htm
2018-04-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118023924/0001209191-18-023924-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118040675/0001209191-18-040675-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118040676/0001209191-18-040676-index.htm
2018-08-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118048444/0001209191-18-048444-index.htm
2018-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118050184/0001209191-18-050184-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919118053681/0001209191-18-053681-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119000037/0001209191-19-000037-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119000039/0001209191-19-000039-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119001637/0001209191-19-001637-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119001638/0001209191-19-001638-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119001639/0001209191-19-001639-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119001640/0001209191-19-001640-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119001641/0001209191-19-001641-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119003517/0001209191-19-003517-index.htm
2019-01-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119004899/0001209191-19-004899-index.htm
2019-01-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119004901/0001209191-19-004901-index.htm
2019-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119011123/0001209191-19-011123-index.htm
2019-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119011127/0001209191-19-011127-index.htm
2019-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119011128/0001209191-19-011128-index.htm
2019-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119011129/0001209191-19-011129-index.htm
2019-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119025201/0001209191-19-025201-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119038194/0001209191-19-038194-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119038195/0001209191-19-038195-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119038196/0001209191-19-038196-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119038197/0001209191-19-038197-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119038198/0001209191-19-038198-index.htm
2019-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119046455/0001209191-19-046455-index.htm
2019-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119047071/0001209191-19-047071-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119060615/0001209191-19-060615-index.htm
2019-12-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119060912/0001209191-19-060912-index.htm
2019-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919119060913/0001209191-19-060913-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120006266/0001209191-20-006266-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120006269/0001209191-20-006269-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120006273/0001209191-20-006273-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120006274/0001209191-20-006274-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120041731/0001209191-20-041731-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120041735/0001209191-20-041735-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120041737/0001209191-20-041737-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120041739/0001209191-20-041739-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120041741/0001209191-20-041741-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1178253/000120919120041744/0001209191-20-041744-index.htm
2018-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1178253/000156459018005461/0001564590-18-005461-index.htm
2018-03-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1178253/000156459018005474/0001564590-18-005474-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1178253/000156459018011781/0001564590-18-011781-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459018015854/0001564590-18-015854-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1178253/000156459018021024/0001564590-18-021024-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459018021110/0001564590-18-021110-index.htm
2018-09-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1178253/000156459018022955/0001564590-18-022955-index.htm
2018-09-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1178253/000156459018023158/0001564590-18-023158-index.htm
2018-09-14424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1178253/000156459018023159/0001564590-18-023159-index.htm
2018-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459018023458/0001564590-18-023458-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1178253/000156459018029141/0001564590-18-029141-index.htm
2018-12-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459018031299/0001564590-18-031299-index.htm
2019-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459019000398/0001564590-19-000398-index.htm
2019-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459019001034/0001564590-19-001034-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459019003199/0001564590-19-003199-index.htm
2019-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459019006994/0001564590-19-006994-index.htm
2019-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1178253/000156459019007834/0001564590-19-007834-index.htm
2019-03-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1178253/000156459019007845/0001564590-19-007845-index.htm
2019-03-22S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1178253/000156459019009007/0001564590-19-009007-index.htm
2019-03-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1178253/000156459019009573/0001564590-19-009573-index.htm
2019-03-29424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1178253/000156459019010152/0001564590-19-010152-index.htm
2019-04-26PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1178253/000156459019013347/0001564590-19-013347-index.htm
2019-04-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459019013375/0001564590-19-013375-index.htm
2019-05-07DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1178253/000156459019016552/0001564590-19-016552-index.htm
2019-05-07DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1178253/000156459019016579/0001564590-19-016579-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1178253/000156459019017162/0001564590-19-017162-index.htm
2019-06-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459019023102/0001564590-19-023102-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1178253/000156459019030032/0001564590-19-030032-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1178253/000156459019030092/0001564590-19-030092-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1178253/000156459019042606/0001564590-19-042606-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459019046013/0001564590-19-046013-index.htm
2020-03-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1178253/000156459020009875/0001564590-20-009875-index.htm
2020-03-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1178253/000156459020009957/0001564590-20-009957-index.htm
2020-04-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459020016151/0001564590-20-016151-index.htm
2020-04-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1178253/000156459020016329/0001564590-20-016329-index.htm
2020-04-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459020016331/0001564590-20-016331-index.htm
2020-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459020018514/0001564590-20-018514-index.htm
2020-04-2810-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1178253/000156459020019188/0001564590-20-019188-index.htm
2020-05-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1178253/000156459020020492/0001564590-20-020492-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459020020497/0001564590-20-020497-index.htm
2020-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1178253/000156459020022814/0001564590-20-022814-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1178253/000156459020023868/0001564590-20-023868-index.htm
2020-05-11424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1178253/000156459020024224/0001564590-20-024224-index.htm
2020-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459020032489/0001564590-20-032489-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1178253/000156459020035769/0001564590-20-035769-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1178253/000156459020038629/0001564590-20-038629-index.htm
2020-09-11S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1178253/000156459020043271/0001564590-20-043271-index.htm
2020-09-28CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1178253/000156459020044804/0001564590-20-044804-index.htm
2020-10-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1178253/000156459020045753/0001564590-20-045753-index.htm
2020-10-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1178253/000156459020045755/0001564590-20-045755-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1178253/000156459020051687/0001564590-20-051687-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000162363219000248/0001623632-19-000248-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000162363220000264/0001623632-20-000264-index.htm
2019-03-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000176046019000002/0001760460-19-000002-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1178253/000176046020000001/0001760460-20-000001-index.htm
2018-09-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1178253/999999999518002377/9999999995-18-002377-index.htm
2019-03-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1178253/999999999519000559/9999999995-19-000559-index.htm
2020-05-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1178253/999999999520001118/9999999995-20-001118-index.htm
2020-10-01EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1178253/999999999520002653/9999999995-20-002653-index.htm
2018-05-22CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1178253/999999999718005820/9999999997-18-005820-index.htm
2019-03-04CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1178253/999999999719000686/9999999997-19-000686-index.htm

SCYNEXIS, Inc (SCYX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of SCYNEXIS, Inc (SCYX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 372%
Institutional Ownership: 3922%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-03-29Gonzalez David AnguloChief Medical OfficerBuy6,000.001.368,160.00101,790.00https://www.sec.gov/Archives/edgar/data/1178253/000120919118022265/0001209191-18-022265-index.htm
2019-02-15Scott SukenickGeneral CounselBuy100,000.00102,959.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119011128/0001209191-19-011128-index.htm
2018-09-06Gonzalez David AnguloChief Medical OfficerBuy7,000.001.278,890.00108,790.00https://www.sec.gov/Archives/edgar/data/1178253/000120919118050184/0001209191-18-050184-index.htm
2018-12-31Gonzalez David AnguloChief Medical OfficerBuy12,000.000.505,950.80121,790.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119000037/0001209191-19-000037-index.htm
2019-02-15Eric FrancoisChief Financial OfficerBuy125,000.00149,917.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119011127/0001209191-19-011127-index.htm
2018-03-08Eric FrancoisChief Financial OfficerBuy5,917.001.699,999.7324,917.00https://www.sec.gov/Archives/edgar/data/1178253/000120919118018707/0001209191-18-018707-index.htm
2019-02-15Gonzalez David AnguloChief Medical OfficerBuy150,000.00271,790.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119011123/0001209191-19-011123-index.htm
2018-03-08Scott SukenickGeneral CounselBuy2,959.001.695,000.712,959.00https://www.sec.gov/Archives/edgar/data/1178253/000120919118018709/0001209191-18-018709-index.htm
2018-03-08DAVID C HASTINGSDirectorBuy11,834.001.6919,999.4631,834.00https://www.sec.gov/Archives/edgar/data/1178253/000120919118018711/0001209191-18-018711-index.htm
2018-03-08Marco TagliettiChief Executive OfficerBuy100,000.001.69169,000.00404,000.00https://www.sec.gov/Archives/edgar/data/1178253/000120919118018708/0001209191-18-018708-index.htm
2018-08-23Marco TagliettiChief Executive OfficerBuy25,000.001.2932,250.00429,000.00https://www.sec.gov/Archives/edgar/data/1178253/000120919118048444/0001209191-18-048444-index.htm
2018-12-31Marco TagliettiChief Executive OfficerBuy25,000.000.4611,500.00455,000.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119000039/0001209191-19-000039-index.htm
2019-01-10Marco TagliettiChief Executive OfficerBuy25,000.000.6917,250.00480,000.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119003517/0001209191-19-003517-index.htm
2019-04-17Marco TagliettiChief Executive OfficerBuy25,000.001.6340,750.00506,000.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119025201/0001209191-19-025201-index.htm
2019-08-15Marco TagliettiChief Executive OfficerBuy10,015.001.0110,115.15516,015.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119046455/0001209191-19-046455-index.htm
2019-08-20Marco TagliettiChief Executive OfficerBuy500.001.11555.00516,515.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119047071/0001209191-19-047071-index.htm
2019-08-21Marco TagliettiChief Executive OfficerBuy9,500.001.1110,545.00526,015.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119047071/0001209191-19-047071-index.htm
2019-12-12Marco TagliettiChief Executive OfficerBuy166,667.000.90150,000.30693,682.00https://www.sec.gov/Archives/edgar/data/1178253/000120919119060615/0001209191-19-060615-index.htm
2018-03-08Gonzalez David AnguloChief Medical OfficerBuy7,000.001.399,730.0095,790.00https://www.sec.gov/Archives/edgar/data/1178253/000120919118018877/0001209191-18-018877-index.htm